cretostimogene grenadenorepvec + n-dodecyl-B-D-maltoside

Cretostimogene grenadenorepvec + n-dodecyl-B-D-maltoside is a **combination product** comprising two components: - **Cretostimogene grenadenorepvec** is an oncolytic adenovirus-based immunotherapy developed as an intravesical treatment for non-muscle invasive bladder cancer (NMIBC), particularly in Bacillus Calmette-Guérin (BCG)-unresponsive disease. It selectively replicates in cancer cells via targeting the Coxsackievirus and Adenovirus Receptors (CAR) and integrin αvβ5, causing tumor cell lysis and immunogenic cell death. The virus is engineered to express granulocyte-macrophage colony stimulating factor (GM-CSF), further amplifying local and systemic anti-tumor immune responses[1][2][4][5][7]. - **n-Dodecyl-B-D-maltoside** is a non-ionic detergent widely used in biotechnology and drug formulation to solubilize membrane proteins and improve the solubility/stability of biologics. In this combination, it may be used as an excipient to enhance delivery or administration (not as an active anti-cancer agent)[3][6][9]. This combination is delivered **intravesically**, with n-dodecyl-B-D-maltoside present as a bladder wash prior to treatment administration to facilitate drug delivery and penetration[4].